Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-1501 in Kidney Transplant
NCT05027906Phase 2Recruiting
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Feb 2022
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tegoprubart in kidney transplant rejection, sponsored by Eledon Pharmaceuticals, Inc.. Started Feb 2022; status: recruiting.
02
Drugs
tegoprubart
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05027906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027906.